InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (2 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
2
T+90 hit rate
75%
T+90 mean return
+8.8%
Across 8 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the detailed record of transactions filed by McClellan Mark B., Directeur. Officer active across 3 companies, notably Cigna Corp. Cumulatively, 17 filings have been recorded. Breakdown: 0 buy · 2 sells. Total volume traded: €268k. Activity tracked since 28 May 2021. The latest transaction was disclosed on 23 April 2025 (Attribution). Regulator: SEC (Form 4). The full history is free.
Declarations17 total
638 shares0Common Stock, $.01 Par ValueSEC:0001225208-25-004425:0
12,258 shares0Common StockSEC:0001628280-25-013266:0
539 shares0Common Stock, $.01 Par ValueSEC:0001225208-24-005290:0
30,000 shares0Common StockSEC:0001209191-24-004878:0
765 shares0Common Stock, $.01 Par ValueSEC:0001225208-23-005158:0
21,802 shares0Common StockSEC:0001209191-23-017843:0
757 shares0Common Stock, $.01 Par ValueSEC:0001225208-22-006305:0
16,556 shares0Common StockSEC:0001209191-22-017994:0
199 shares0Common Stock, $.01 Par ValueSEC:0001225208-22-003937:0
247 shares0Common Stock, $.01 Par ValueSEC:0001225208-21-014398:0
247 shares0Common Stock, $.01 Par ValueSEC:0001225208-21-014398
7,500 shares@ US$20.10750.0041% mcap50.0% of flowCommon StockSEC:0000950142-21-003817:0
7,500 shares@ US$20.107550.0% of flowCommon StockSEC:0000950142-21-003817
224 shares0Common Stock, $.01 Par ValueSEC:0001225208-21-011983:0
224 shares0Common Stock, $.01 Par ValueSEC:0001225208-21-011983
183 shares0Common Stock, $.01 Par ValueSEC:0001225208-21-008831:0
183 shares0Common Stock, $.01 Par ValueSEC:0001225208-21-008831
17 of 17 declarations
About McClellan Mark B.
McClellan Mark B. serves as a Director at Cigna Corp and Alignment Healthcare, Inc. He contributes to the strategic direction of these companies by bringing his expertise in the healthcare sector. As a board member, Mark participates in policy development and oversight of operations. His experience in the healthcare field is valuable in guiding these companies toward growth.
